… and developing therapeutic strategies to … anti-HER2 agents and the optimal sequencing
of therapies. Here, we summarise recent therapeutic advances in targeting HER2 alterations in …

… breakthrough, nearly all patients with metastatic HER2-positive breast cancer eventually
progress on anti-HER2 therapy … intrinsic subtype, 17 alterations in the HER2-receptor (such as …

… HER2 alterations in NSCLC and summarizes recent progress in … therapies offer higher
response rates and improved survival in HER2 altered NSCLC; these therapeutic breakthroughs …

… of HER2 as an actionable and highly sensitive therapeutic … breakthrough for the treatment
of highly aggressive HER2-… therapeutic approaches approved for treatment of HER2 + BC, …

… In May 2020 trastuzumab deruxtecan (T-DXd) received the US Food and Drug Administration
breakthrough therapy designation for HER2-mutant metastatic NSCLC, and was added as …

… HER2 alterations across tumor types. A, Prevalence of … In 2017, FDA granted DS-8201
breakthrough designation for HER2-positive breast cancer. DS-8201a demonstrated remarkable …

… This review highlights the dynamic and evolving landscape of HER2-targeted therapies in
NSCLC, marking significant advances from the initial use of monotherapies to more recent …

… Moreover, the tribody altered the tumor microenvironment (TME) and converted it to an …
recognition of cancer cells has been a breakthrough in the oncology arena. Antibodies against PD…

… impact of these HER2 alterations in various therapeutic approaches. … HER2-altered NSCLCs,
the development of HER2-targeted therapies such as tyrosine kinase inhibitors, anti-HER2 …

… HER2 alterations in NSCLC including the diagnostic challenges and therapeutic options. …
Thus, all the novel data and breakthroughs support the need to develop standardized and …